Semax (Research-Grade Peptide)

Synthetic ACTH(4-10) analogue — for laboratory research only

Product Overview

Semax is a synthetic peptide derived from a fragment of adrenocorticotropic hormone (ACTH 4–10).
Originally developed in Russia, it has been widely studied in laboratory settings for its potential
effects on the central nervous system, neuroprotection, and modulation of brain-derived neurotrophic
factor (BDNF). This material is provided as high-purity lyophilized powder for research purposes only.

Research Highlights

• Neuroprotection & Ischemia Models: Preclinical studies report that Semax may
  reduce neuronal damage and improve recovery in ischemia models.
  PubMed
• BDNF Modulation: Laboratory work indicates Semax influences expression of
  brain-derived neurotrophic factor (BDNF), which is critical for synaptic plasticity and neuronal survival.
  PMC
• Cognitive Function Research: Experimental data suggest potential roles in learning,
  memory, and adaptive responses to stress.
  PubMed
• Anti-inflammatory Pathways: Some studies point to modulation of inflammatory markers
  in the brain following peptide administration.
  PubMed

Product Details & Handling

• Form: Lyophilized powder, supplied in sterile vials
• Purity: ≥ 98% (Certificate of Analysis provided)
• Storage: Store at –20 °C; protect from light and moisture
• Handling: Use in controlled laboratory settings with appropriate PPE;
  consult SDS for detailed safety instructions

Legal Disclaimer

This product is provided strictly for laboratory research use only.
It is not intended for human or veterinary consumption, therapeutic, diagnostic, or clinical application.
Customers are responsible for compliance with all applicable laws and institutional policies.
Semax is not approved by the FDA as a drug, supplement, or treatment.
Windy City Peptide does not provide medical advice or support related to human use.